All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

19

Reset

19 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • SurovatamigAZD0486, TNB-486Phase 39 trials

    AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • NX-5948bexobrutidegPhase 33 trials

    Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • TQB3909Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia, Myeloid Malignancy

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • EmavusertibCA-4948Phase 22 trials

    Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

  • GNC-035Phase 22 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma

  • IDP-121Phase 22 trials

    IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

  • LacutoclaxPhase 22 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)

  • ALLO-647Phase 21 trial

    Allogene Therapeutics · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

  • MS-553Phase 21 trial

    MingSight Pharmaceuticals, Inc · CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.